AbbVie Inc.

4AB.F·Frankfurt·Healthcare
Compare
264.00+9.30 (+3.65%)today
As of Nov 5, 8:48 AM CET · May be delayed up to 15 min · EUR

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close254.70
Open264.00
Day range—
52-week range167.55272.30
Off day high0.00%
Off 52-week high−3.05%
Volume24.00
Avg. volume (3M)79.00
Market cap466.52B
EPS (TTM)5.01
Forward P/E18.90
P/E ratio (TTM)52.69
Dividend yield2.32% (5.99)
Beta (5Y)0.19
Shares outstanding1.77B
Short interest—
Earnings dateOct 30, 2026
Analyst target—
Profit margin15.67%

Against its peers

Compare in full ›
4AB.F BMY PFE 0QYQ.IL BIIB GLENMARK.BO
Market cap 466.52B 131.21B 175.50B 215.56B 37.61B 701.47B
P/E (TTM) 52.7 14.2 44.0 39.8 110.2 39.0
Forward P/E 18.9 9.6 10.6 — 15.6 25.6
Price/book -114.4 5.6 2.1 10.2 2.0 6.7
Dividend yield 2.32% 3.93% 5.59% 3.81% — 0.20%
1-year change +38.48% +37.66% +23.90% +38.91% +62.35% +32.82%
Today +3.65% +4.02% +2.63% +0.58% +2.22% −0.65%

The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.

Latest news

All 4AB.F news ›
PMLiVE··2 outletsPositive

AbbVie expands Oxford R&D as part of more than £120m investment in UK life sciences

PMLiVE AbbVie expands Oxford R&D as part of more than £120m investment in UK life sciences AbbVie has announced the expansion of its UK R&D facility, AbbVie Oxford. The new 12,000-square-foot site will expand AbbVie

More from 1 other outlet
The Globe and Mail·Negative

AbbVie (ABBV) Receives a Rating Update from a Top Analyst

Leerink Partners analyst David Risinger reiterated a Buy rating on AbbVie today and set a price target of $325.00. According to TipRanks, Risinger is a top 100 analyst with an average return of 32.8% and a 65.44% success rate. Risinger…

From the 4Search news index, newest first.

In the news

248mentions in 30 days
248with it in the headline
Positivesentiment

Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance